Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A recent market note says Moderna has gained more than 80% in 2026, but two major events in the next two weeks could decide whether momentum holds or reverses.
THE APEX TIMES
THE APEX TIMES
CVS Health (CVS) closed at $109.34 on the most recent trading day covered by the latest market roundup from Yahoo Finance, a gain of 2.12% versus the prior session.
THE APEX TIMES
A market analysis tied UnitedHealth’s recent rally to a past Berkshire Hathaway investment, arguing the conglomerate may have sold after the odds looked worse. The debate is less about fundamentals than about timing.
THE APEX TIMES
Investors weighed UnitedHealth Group’s latest quarterly results, where revenue climbed to $112.03 billion and net income reached $5.48 billion, alongside a higher outlook and ongoing share repurchases.
THE APEX TIMES
A reported acquisition plan would place Eli Lilly in the fast-moving psychedelics pipeline, even as investors debate which early entrants have the clearest path to approved medicines.
THE APEX TIMES
A recent market comparison highlights how Johnson & Johnson’s revenue has edged upward at a measured pace while Eli Lilly’s sales growth has been markedly faster, shrinking a once-wide gap between the two healthcare giants.
THE APEX TIMES
A report highlighted six ongoing Phase 3 trials for Amgen’s once-monthly weight-loss candidate, raising questions about how quickly new entrants could shift treatment choices in a crowded obesity and weight-management market.
THE APEX TIMES
A recent market commentary says Lilly’s next phase of drug development could broaden its growth story, even as competition and demand dynamics remain central to the weight-loss market.
THE APEX TIMES
Moderna’s stock slipped after a report said European regulators granted approvals for the company’s flu-COVID combination vaccine, marking a regulatory milestone. The move follows an earlier run of strong financial results highlighted by year-over-year Q1 growth that beat expectations.
